The Middle East & Africa radiopharmaceutical theranostics market was valued at US$ 89.44 million in 2022 and is expected to reach US$ 157.30 million by 2028; it is estimated to register a CAGR of 9.9% from 2022 to 2028.
Based on radioisotype, the Middle East & Africa radiopharmaceutical theranostics market is segmented into technetium-99, gallium-68, iodine-131, iodine-123, Fluorine-18 (18F), Yttrium 90 (Y-90), Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, and others. The Lutetium (Lu) 177 segment held the largest market share in 2022.
Based on source, the Middle East & Africa radiopharmaceutical theranostics market is bifurcated into nuclear reactors and cyclotrons. The cyclotrons segment held a larger market share in 2022.
Based on application, the Middle East & Africa radiopharmaceutical theranostics market is bifurcated into targeted therapeutic [Rx] and Companion Diagnostic [CDx]. The targeted therapeutic [Rx] segment held a larger market share in 2022.
Based on indication, the Middle East & Africa radiopharmaceutical theranostics market is segmented into oncology, cardiology, neurology, and others. The oncology segment held the largest market share in 2022.
Based on end user, the Middle East & Africa radiopharmaceutical theranostics market is segmented into hospitals, diagnostic imaging centers, academic and research institutes, and others. The hospitals segment held the largest market share in 2022.
Based on country, the Middle East & Africa radiopharmaceutical theranostics market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa radiopharmaceutical theranostics market share in 2022.
Bayer AG; Curium; Telix Pharmaceuticals Ltd.; and Siemens Healthineers are some of the leading companies operating in the Middle East & Africa radiopharmaceutical theranostics market.
Reasons to Buy
Rising Incidence of Cancer fuel the Middle East & Africa Radiopharmaceutical Theranostics Market
The most common types of cancer are breast, lung, colon, rectum, and prostate. As people age, they become immunocompromised and often succumb to cancer risks. Poor lifestyles, longer working hours, increasingly stressful lives, smoking, alcohol consumption, contraceptive use, nulliparity, and reduced breastfeeding all contribute to breast cancer incidence. Theranostics is the combination of therapeutic and diagnostic techniques that utilize a suitable radiopharmaceutical agent. For example, radioiodine has a well-known theranostic application in diagnosing and treating differentiated thyroid cancer. Several radiopharmaceutical theranostic pairs are available for breast cancer applications. These pairs include 43/44 Sc/47 Sc, 64 Cu/67 Cu, 83 Sr/89 Sr, 86Y/90 Y, 110 In/111 In, 124I/131 I, 152 Tb/161 Tb, 152 Tb/149 Tb, 68 Ga/177 Lu, and 90 Y/177 Lu. 123 I/131 I is a well-known example of theranostic pair that is used in high-quality single-photon emission computerized tomography (SPECT)/CT for pre- and post-therapeutic assessment of thyroid cancer. Malignant gliomas are deadly tumors with the availability of only a few therapeutic options. 89 Zr- and 177 Lu-labeled Lumi804-αCD11b is a promising theranostic technique intended for monitoring and reducing tumor-associated myeloid cells (TAMCs) in gliomas and improving immunotherapy outcomes. Further, theranostics are incorporated in radiometals for PET imaging and targeted radiopharmaceutical therapy (TRT). DOTA-octreotate (dotatate) radiolabeled with Lu-177 (177Lu-dotatate: Lutathera) or Ga-68 (68Ga-dotatate: NetSpot) are approved by the Food and Drug Administration (FDA) for targeted radiopharmaceutical therapy (TRT) and positron emission tomography (PET) imaging. Thus, a radiopharmaceutical theranostic approach has unprecedented value in diagnosing and treating different types of cancer, which fuels the overall market growth.Middle East & Africa Radiopharmaceutical Theranostics Market Overview
The Middle East & Africa radiopharmaceutical theranostics market is segmented into the Saudi Arabia, South Africa, UAE, and the rest of Middle East & Africa. The market growth in this region is due to the increasing incidences of chronic diseases, presence of supportive government plans, growing strategic initiatives by the market players, and development of innovative radiotherapies. The major factors for diabetes are obesity, unhealthy lifestyle, increased life expectancy, increased healthcare expenditures, and genetic susceptibility. Thus, increasing cardiovascular diseases due to rising diabetes condition in Saudi Arabia is driving the growth of radiopharmaceutical theranostics market.Middle East & Africa Radiopharmaceutical Theranostics Market Revenue and Forecast to 2028 (US$ Million)
Middle East & Africa Radiopharmaceutical Theranostics Market Segmentation
The Middle East & Africa radiopharmaceutical theranostics market is segmented based on product type, radioisotype, source, application, indication, end user, and country. Based on product type, the Middle East & Africa radiopharmaceutical theranostics market is segmented into alpha emitters, beta emitters, and Positron Emission Tomography (PET) tracers. The Positron Emission Tomography (PET) tracers segment held the largest market share in 2022.Based on radioisotype, the Middle East & Africa radiopharmaceutical theranostics market is segmented into technetium-99, gallium-68, iodine-131, iodine-123, Fluorine-18 (18F), Yttrium 90 (Y-90), Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, and others. The Lutetium (Lu) 177 segment held the largest market share in 2022.
Based on source, the Middle East & Africa radiopharmaceutical theranostics market is bifurcated into nuclear reactors and cyclotrons. The cyclotrons segment held a larger market share in 2022.
Based on application, the Middle East & Africa radiopharmaceutical theranostics market is bifurcated into targeted therapeutic [Rx] and Companion Diagnostic [CDx]. The targeted therapeutic [Rx] segment held a larger market share in 2022.
Based on indication, the Middle East & Africa radiopharmaceutical theranostics market is segmented into oncology, cardiology, neurology, and others. The oncology segment held the largest market share in 2022.
Based on end user, the Middle East & Africa radiopharmaceutical theranostics market is segmented into hospitals, diagnostic imaging centers, academic and research institutes, and others. The hospitals segment held the largest market share in 2022.
Based on country, the Middle East & Africa radiopharmaceutical theranostics market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa radiopharmaceutical theranostics market share in 2022.
Bayer AG; Curium; Telix Pharmaceuticals Ltd.; and Siemens Healthineers are some of the leading companies operating in the Middle East & Africa radiopharmaceutical theranostics market.
Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africaradiopharmaceutical theranostics market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africaradiopharmaceutical theranostics market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the Middle East & Africaradiopharmaceutical theranostics market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
Table of Contents
1. Introduction
3. Research Methodology
4. Middle East & Africa Radiopharmaceutical Theranostics Market - Market Landscape
5. Middle East & Africa Radiopharmaceutical Theranostics Market - Key Market Dynamics
6. Radiopharmaceutical Theranostics Market - Middle East & Africa Analysis
7. Middle East & Africa Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 - by Product Type
8. Middle East & Africa Radiopharmaceutical Theranostics Market Analysis - by Radioisotope
9. Middle East & Africa Radiopharmaceutical Theranostics Market Analysis - by Source
10. Middle East & Africa Radiopharmaceutical Theranostics Market Analysis - by Application
11. Middle East & Africa Radiopharmaceutical Theranostics Market Analysis - by Indication
12. Middle East & Africa Radiopharmaceutical Theranostics Market Analysis - by End User
13. Middle East & Africa Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 - by Country Analysis
14. Radiopharmaceutical Theranostics Market - Industry Landscape
15. Company Profiles
16. Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bayer AG
- Curium
- Telix Pharmaceuticals Ltd.
- Siemens Healthineers
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 146 |
| Published | October 2023 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value in 2022 | 89.44 Million |
| Forecasted Market Value by 2028 | 157.3 Million |
| Compound Annual Growth Rate | 9.9% |
| Regions Covered | Africa, Middle East |
